Company intelligence / Profile preview

TekCyte

Mawson Lakes / Adelaide, South Australia, Australiatekcyte.com ↗

Ownership: Private
Development stage: Other

Overview

TekCyte's BIOINVISIBLE coating has demonstrated extreme reduction in biofilm formation and clotting in laboratory testing. The Alyra IUD contraceptive device has completed a first human trial with ongoing recruitment for a second phase clinical study targeting period pain relief.

Therapeutic areas: Women's HealthCardiovascularInfectious Diseases
Modalities: Device (medical device coatings)Polymer-drug conjugate therapy (hydrophilic hyperbranched polyglycerol polymer coating)Non-pharmacological therapy (drug-free anti-infective/anti-thrombotic surface)
Industry: Implantable Medical Devices

Partnerships

Not explicitly listed; feedback from US-based surgeons noted.

Beyond the preview

Go deeper on TekCyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TekCyte.

Explore the full profile